Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Cholet – page 5

69 clinical trials in Cholet, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Cholet at a glance
69
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

69 trials in Cholet

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:Solti Group

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Colitis ulcerative

Not recruiting

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Non-small cell lung cancer stage IV+1

Not recruiting

Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Cholet

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on lung cancer treatments, including innovative combinations of immunotherapy and chemotherapy. Multiple trials exploring new approaches for breast cancer management, particularly in triple-negative and hormone-positive cases.

  • Advanced NSCLC Treatments
  • Colorectal Cancer Therapies
  • Breast Cancer Innovations

Several studies investigating novel drug combinations and personalized treatment approaches for various cancer types.

02 Cardiovascular Studies

Comprehensive research into heart failure prevention and treatment, including studies on novel drug combinations. Investigations of stroke prevention in patients with atrial fibrillation and management of cardiovascular risks.

  • Heart Failure Management
  • Stroke Prevention
  • Cardiovascular Disease Treatment

Focus on developing innovative therapeutic approaches for various cardiac conditions.

03 Respiratory Medicine

Advanced research in severe asthma treatment and respiratory care, including studies of new therapeutic agents. Investigation of oxygen therapy protocols in intensive care settings.

  • Asthma Treatment Innovation
  • Respiratory Support Protocols
  • Acute Respiratory Care

Emphasis on improving treatment outcomes for patients with severe respiratory conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.